Both Y-mAbs Therapeutics Inc. (NASDAQ:YMAB) and Dare Bioscience Inc. (NASDAQ:DARE) are each other’s competitor in the Biotechnology industry. Thus the compare of their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Y-mAbs Therapeutics Inc.||23||0.00||N/A||-1.95||0.00|
|Dare Bioscience Inc.||1||0.00||N/A||-1.06||0.00|
Table 1 demonstrates Y-mAbs Therapeutics Inc. and Dare Bioscience Inc.’s gross revenue, earnings per share and valuation.
Table 2 shows Y-mAbs Therapeutics Inc. and Dare Bioscience Inc.’s net margins, return on assets and return on equity.
|Net Margins||Return on Equity||Return on Assets|
|Y-mAbs Therapeutics Inc.||0.00%||0%||0%|
|Dare Bioscience Inc.||0.00%||-150.1%||-130.6%|
13.3 and 13.3 are the respective Current Ratio and a Quick Ratio of Y-mAbs Therapeutics Inc. Its rival Dare Bioscience Inc.’s Current and Quick Ratios are 4.2 and 4.2 respectively. Y-mAbs Therapeutics Inc. has a better chance of clearing its pay short and long-term debts than Dare Bioscience Inc.
The Recommendations and Ratings for Y-mAbs Therapeutics Inc. and Dare Bioscience Inc. are featured in the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Y-mAbs Therapeutics Inc.||0||0||2||3.00|
|Dare Bioscience Inc.||0||0||0||0.00|
Y-mAbs Therapeutics Inc.’s upside potential is 27.50% at a $37 average target price.
Institutional & Insider Ownership
Institutional investors owned 34% of Y-mAbs Therapeutics Inc. shares and 8.2% of Dare Bioscience Inc. shares. Y-mAbs Therapeutics Inc.’s share owned by insiders are 51.22%. Comparatively, insiders own roughly 0.8% of Dare Bioscience Inc.’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Y-mAbs Therapeutics Inc.||-2.7%||-2.14%||-1.37%||10.36%||0%||9.98%|
|Dare Bioscience Inc.||2.17%||-6.1%||-25.07%||-3.97%||-31.58%||7.85%|
For the past year Y-mAbs Therapeutics Inc.’s stock price has bigger growth than Dare Bioscience Inc.
Y-mAbs Therapeutics Inc. beats on 6 of the 7 factors Dare Bioscience Inc.
Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. The company has a license and research collaboration agreement with Memorial Sloan-Kettering Cancer Center. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.
DarÃ© Bioscience, Inc. develops and commercializes product for womenÂ’s reproductive health, Ovaprene. The company was incorporated in 2015 and is based in La Jolla, California.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.